NCT04273555 2026-02-06
Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging
University of Alabama at Birmingham
Phase 1/2 Withdrawn
Clinical Trials
12 trialsNCT05950113 2024-05-01
CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT04140513 2024-03-08
Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer
Ohio State University Comprehensive Cancer Center
Phase NA Withdrawn
NCT02607423 2023-05-25
Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery
Eastern Cooperative Oncology Group
Phase 2 Withdrawn
NCT02899325 2023-02-21
FDGal PET/CT to Detect Hepatocellular Carcinoma
British Columbia Cancer Agency
Withdrawn
NCT00373711 2022-06-21
Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA
Stanford University
Withdrawn
NCT03295695 2020-12-04
PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Withdrawn
NCT03107325 2020-10-06
Biokinetics Study for F-18 FDG in Pediatric Molecular Imaging
Boston Children's Hospital
Phase 4 Withdrawn
NCT01789892 2018-06-28
Methylprednisolone Before Fludeoxyglucose-Labeled Positron Emission Tomography in Patients With Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase NA Withdrawn
NCT02059889 2016-12-16
Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer
Virginia Commonwealth University
Phase NA Withdrawn
NCT01314677 2012-06-29
Fludeoxyglucose F 18 PET/CT Scans in Predicting Therapy Response in Patients With Stage IIIA Non-Small Cell Lung Cancer Undergoing Chemoradiation
City of Hope Medical Center
Phase NA Withdrawn
NCT00110006 2010-06-11
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma
Case Comprehensive Cancer Center
Phase NA Withdrawn